Investors following the managed care space often compare large, diversified insurers with smaller, specialized operators. This analysis looks at ELV (Elevance Health) and MOH (Molina Healthcare), two names with exposure to government-sponsored programs yet very different scales, business mixes, and market positions. The comparison matters for those assessing relative performance in health insurance and weighing risk tolerance, growth drivers, and sensitivity to Medicaid and Medicare policy shifts.
Elevance Health, formerly Anthem, runs one of the largest health benefits platforms in the United States, serving roughly 104 million consumers through its Health Benefits segment and Carelon services division, which includes CarelonRx pharmacy benefit manager and Carelon Services. Shares have shown notable strength lately, trading near 52-week highs after stronger-than-expected third-quarter results. Adjusted EPS grew about 16% year over year, and the company lifted its 2026 adjusted EPS outlook to at least $29. Management views 2026 as the trough for Medicaid margins, with improvement expected in 2027, while Carelon adds diversified services-based growth. As a dividend payer with a broad commercial book, ELV presents a relatively balanced profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Molina Healthcare focuses mainly on Medicaid, with additional Medicare and Marketplace segments, serving about 4.9 million members. The stock has recovered sharply from early-year lows after a tough fourth quarter of 2025. Third-quarter results beat estimates on revenue and adjusted EPS, though revenue declined year over year and membership contracted amid Medicaid redeterminations. The medical care ratio stayed elevated near 93%, and management sees current Medicaid margins as the likely trough of a multi-year cycle. MOH pays no dividend and remains more concentrated in government programs, increasing its sensitivity to rate and policy changes.
The clearest difference lies in diversification versus concentration. ELV covers commercial, Medicaid, Medicare, and a growing services arm, helping cushion earnings against pressure in any one program. MOH, by contrast, draws most revenue from Medicaid, offering greater upside from a rate recovery but also higher exposure to membership shifts and utilization trends. On momentum, ELV has shown steadier trend strength with raised guidance and a climb toward multi-month highs, while MOH posted larger percentage gains from a lower base amid thinner margins. Risk profiles differ too: ELV carries a dividend and more defensive balance sheet, whereas MOH faces greater execution risk around new contracts and eligibility changes.
Based on trend consistency, earnings momentum, business diversification, and relative stability, Tickeron’s AI currently favors ELV over MOH. Elevance Health’s raised guidance, services-driven growth, and steady advance suggest a more durable trend, while Molina Healthcare’s recovery hinges more on Medicaid rate realization and margin inflection. This remains a probabilistic view of relative positioning rather than a firm forecast, and conditions could shift the balance.
When evaluating names like these, I often turn to Tickeron’s Trending AI Robots page to review automated strategies suited to current market conditions. The section curates bots from a larger library, each with its own style, timeframe, and performance data, helping provide additional context on technical and sentiment signals without replacing fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MOH moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 52 cases where MOH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MOH as a result. In 56 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for MOH just turned positive on November 16, 2026. Looking at past instances where MOH's MACD turned positive, the stock continued to rise in 33 of 47 cases over the following month. The odds of a continued upward trend are 70%.
The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 215 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 149 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
MOH broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (3.520). MOH's P/E Ratio (1306.188) is considerably higher than the industry average of (126.353). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare